Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Thrombolytic Therapy With Half Dose Alteplase, Added to Standard Anticoagulation Therapy With Heparine, in Patients With Moderate Pulmonary Embolism: a Prospective, Randomized, Open Label,Controlled Trial

NCT02604238 is registered in ClinicalTrials.gov with Azienda U.S.L. 1 di Massa e Carrara as lead sponsor.

NCT NCT02604238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02604238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Thrombolytic Therapy With Half Dose Alteplase, Added to Standard Anticoagulation Therapy With Heparine, in Patients With Moderate Pulmonary Embolism: a Prospective, Randomized, Open Label,Controlled Trial
Lead sponsor
Azienda U.S.L. 1 di Massa e Carrara
Phase
Phase 3
Overall status
Withdrawn
Start date
March 31, 2016
Completion date
March 31, 2016
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary embolism